| Conferences > Rx Summit Europe 2021: EV, microRNA & RNA Therapeutics > Keynote Speakers |
| Register | Login |
Chulhee ChoiProfessor and Chair, BioMedical Imaging Center, Korea Advanced Institute of Science and Technology (KAIST), President, ILIAS Biologics Incorporated Chulhee Choi is Professor of Department of Bio and Brain Engineering at KAIST in South Korea. In addition, he is a scientific founder and CEO of ILIAS Biologics Incorporated, a company dedicated for development of exosome-based novel therapeutics. His group has been studying cell signaling involved in cell death and proliferation in inflammatory conditions and various malignant cancers. Dr. Choi’s group has also focused on development of novel biomedical imaging tools such as dynamic ICG fluorescence imaging for deep tissue perfusion and novel optical technology using femtosecond ultrashort pulsed lasers for modulation of biological functions. Recently, his team has demonstrated that optogenetic engineering of exosome producing cells can be applied for intracellular delivery of bioactive proteins with therapeutic potentials. His group is now pursuing research and development for clinically available exosome-based therapeutics. He is a graduate of Yonsei University College of Medicine, where he received his MD and PhD. |
Randolph CortelingHead of Research, ReNeuron Ltd. Randolph started his career as a Research associate at Novartis, before undertaking a PhD in Medical and Surgical Sciences at Nottingham University. He then subsequently spent 3 years as a Heart and Stroke Foundation postdoctoral fellow at the University Calgary, Canada before joining ReNeuron as a senior member of the research team in 2007. During his time at ReNeuron, Randolph has developed a number of new discoveries along with a thorough understanding of stem cell biology leading to his appointment as Head of Cell Biology in 2011 before subsequently being made Head of Research in April 2015. |
Samir EL-AndaloussiAssociate Professor, Karolinska Institutet Samir EL Andaloussi received his PhD in 2008 in Neurochemistry with Molecular Neurobiology at Stockholm University. After a postdoctoral stint at Karolinska Institutet, he moved to University of Oxford to work with extracellular vesicles (EVs). Since 2013 Associate Professor Samir is a Principal Investigator for a growing lab at Karolinska Institutet, now with nearly 20 employees. His lab primarily focuses on developing non-viral drug delivery systems for nucleic acids and proteins with particular focus on production of engineered exosomes for delivery of biotherapeutics. In addition, Samir in one of the Founders of Evox Therapeutics, a company developing engineered EVs for treatment of genetic diseases. |
Bernd GiebelGroup Leader, Institute for Transfusion Medicine, University Hospital Duisburg-Essen Bernd Giebel studied biology at the University zu Köln and received his PhD in 1996 at the Institute for Developmental Biology in Köln. He runs a lab at the Institute for Transfusion Medicine at the University Hospital Essen. Since 1999 he works with human hematopoietic stem cells and started in 2009 to explore the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. It is the current goal to optimize the MSC-EV production and characterization process to efficiently translate MSC-EVs into the clinics. |
Mario GimonaHead of Manufacturing, GMP Unit, Paracelsus Medical University Salzburg Mario Gimona received his PhD in Genetics and Cell Biology in 1990 and spent his postdoctoral period at the Cold Spring Harbor Laboratory in New York. He has led research labs in Austria and Italy and was awarded a Marie Curie Excellent Grant by the European Union in 2004. Since 2012 he heads the GMP stem cell and EV production unit at PMU and leads a team of researchers investigating the potential of MSC-derived EVs and CDVs in regenerative medicine for application in acute spinal cord injury and for the reduction of scar formation following implant-induced injury. |
Sai Kiang LimResearch Director, Institute of Medical Biology, A*STAR Dr Sai-Kiang Lim graduated with B.Sc (Hons), NUS. PhD SUNY at Buffalo and did post-doctoral training Columbia University. She led independent research groups at NUMI, NUS (1996-2001), Genome Institute of Singapore (2002-2007) and then Institute of Medical Biology (2007-present). The current research interest in her lab is the study of extracellular vesicles (EVs) for the development of therapeutics and diagnostics as well as artificial lipid membrane vesicles. |
